PRAXIS PRECISION MEDICINES INC

NASDAQ: PRAX (Praxis Precision Medicines, Inc)

Kemas kini terakhir: 2 hari lalu, 10:05AM

314.70

2.10 (0.67%)

Penutupan Terdahulu 312.60
Buka 312.79
Jumlah Dagangan 117,310
Purata Dagangan (3B) 810,483
Modal Pasaran 8,729,430,016
Harga / Jualan (P/S) 842.93
Harga / Buku (P/B) 24.04
Julat 52 Minggu
26.70 (-91%) — 326.91 (3%)
Tarikh Pendapatan 5 Nov 2025
Margin Operasi (TTM) -2,868.84%
EPS Cair (TTM) -10.66
Pertumbuhan Hasil Suku Tahunan (YOY) 1,349.10%
Jumlah Hutang/Ekuiti (D/E MRQ) 0.24%
Nisbah Semasa (MRQ) 8.44
Aliran Tunai Operasi (OCF TTM) -163.91 M
Aliran Tunai Bebas Leveraj (LFCF TTM) -90.04 M
Pulangan Atas Aset (ROA TTM) -39.95%
Pulangan Atas Ekuiti (ROE TTM) -63.56%

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Biotechnology (US) Menaik Bercampur
Biotechnology (Global) Menaik Bercampur
Stok Praxis Precision Medicines, Inc Menurun Menaik

AISkor Stockmoo

-1.1
Konsensus Penganalisis -0.5
Aktiviti Orang Dalam -1.0
Volatiliti Harga -5.0
Purata Bergerak Teknikal -1.0
Osilator Teknikal 2.0
Purata -1.10

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
PRAX 9 B - - 24.04
BBIO 15 B - - -
EXEL 12 B - 18.83 5.43
MDGL 11 B - - 18.00
TGTX 5 B - 11.04 8.16
CORT 4 B - 42.02 5.78

Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.

Sektor Healthcare
Industri Biotechnology
Gaya Pelaburan Small Growth
% Dimiliki oleh Orang Dalam 0.16%
% Dimiliki oleh Institusi 122.02%
Julat 52 Minggu
26.70 (-91%) — 326.91 (3%)
Julat Harga Sasaran
95.00 (-69%) — 843.00 (167%)
Tinggi 843.00 (BTIG, 167.87%) Beli
Median 450.00 (42.99%)
Rendah 95.00 (Wedbush, -69.81%) Jual
Purata 489.56 (55.56%)
Jumlah 8 Beli, 1 Jual
Harga Purata @ Panggilan 272.99
Syarikat Tarikh Harga Sasaran Panggilan Harga @ Panggilan
Wedbush 12 Jan 2026 95.00 (-69.81%) Jual 275.74
05 Dec 2025 83.00 (-73.63%) Jual 247.99
BTIG 29 Dec 2025 843.00 (167.87%) Beli 304.58
08 Dec 2025 507.00 (61.11%) Beli 270.98
Oppenheimer 15 Dec 2025 750.00 (138.32%) Beli 276.40
Guggenheim 09 Dec 2025 760.00 (141.50%) Beli 258.13
Jefferies 09 Dec 2025 450.00 (42.99%) Beli 258.13
HC Wainwright & Co. 08 Dec 2025 340.00 (8.04%) Beli 270.98
05 Dec 2025 340.00 (8.04%) Beli 247.99
Needham 08 Dec 2025 315.00 (0.10%) Beli 270.98
05 Dec 2025 304.00 (-3.40%) Beli 247.99
TD Cowen 08 Dec 2025 353.00 (12.17%) Beli 270.98
Truist Securities 08 Dec 2025 500.00 (58.88%) Beli 270.98
Papar semua
Nama Purata Belian ($) Purata Jualan ($) Jumlah Net Jumlah Nilai Bersih ($)
KELLY TIMOTHY EDWIN - 282.10 -2,278 -645,104
MASTROCOLA LAUREN - 282.10 -711 -200,716
NEMIROFF ALEX - 282.10 -1,685 -476,277
SNIECINSKI MEGAN - 282.10 -1,972 -557,575
SOUZA MARCIO - 288.45 -4,252 -1,226,489
Jumlah Keseluruhan Kuantiti Bersih -10,898
Jumlah Keseluruhan Nilai Bersih ($) -3,106,161
Purata Pembelian Keseluruhan ($) -
Purata Jualan Keseluruhan ($) 282.80
Nama Pemegang Tarikh Jenis Kuantiti Harga Nilai ($)
KELLY TIMOTHY EDWIN Pegawai 12 Jan 2026 Dibuang (-) 943 275.74 260,023
NEMIROFF ALEX Pegawai 12 Jan 2026 Dibuang (-) 768 275.74 211,768
SNIECINSKI MEGAN Pegawai 12 Jan 2026 Dibuang (-) 885 275.74 244,030
MASTROCOLA LAUREN Pegawai 12 Jan 2026 Dibuang (-) 344 275.74 94,855
SOUZA MARCIO Pegawai 10 Jan 2026 Dibuang (-) 4,252 288.45 1,226,489
KELLY TIMOTHY EDWIN Pegawai 10 Jan 2026 Dibuang (-) 1,335 288.45 385,081
NEMIROFF ALEX Pegawai 10 Jan 2026 Dibuang (-) 917 288.45 264,509
SNIECINSKI MEGAN Pegawai 10 Jan 2026 Dibuang (-) 1,087 288.45 313,545
MASTROCOLA LAUREN Pegawai 10 Jan 2026 Dibuang (-) 367 288.45 105,861
Tarikh Jenis Butiran
13 Jan 2026 Pengumuman Praxis Precision Medicines Appoints Global Epilepsy Leader Dr. Orrin Devinsky as Head of Clinical Strategy
12 Jan 2026 Pengumuman Praxis Precision Medicines Enters Its Next Chapter Following a Pivotal Year of Progress
09 Jan 2026 Pengumuman Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08 Jan 2026 Pengumuman Praxis Precision Medicines Further Positioned for Next-Phase Growth with Key Board and Executive Appointments
06 Jan 2026 Pengumuman Praxis Precision Medicines, Inc. Announces Pricing of $575 Million Public Offering
06 Jan 2026 Pengumuman Praxis Precision Medicines, Inc. Announces Proposed Public Offering
29 Dec 2025 Pengumuman Praxis Precision Medicines Announces the FDA Has Granted Breakthrough Therapy Designation for Ulixacaltamide HCl in Essential Tremor
11 Dec 2025 Pengumuman Praxis Precision Medicines Announces Plans to File an NDA for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies in Early 2026
09 Dec 2025 Pengumuman Praxis Precision Medicines Announces Alignment with FDA on Simplified and Accelerated Registrational Pathway for Elsunersen in Early Onset SCN2A Developmental and Epileptic Encephalopathy
08 Dec 2025 Pengumuman Praxis AES Wrap-up: Best-in-Class Potential Across Rare Pediatric and Adult Epilepsies
04 Dec 2025 Pengumuman Praxis Precision Medicines Announces Positive Results from EMBOLD Study for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies
04 Dec 2025 Pengumuman Praxis Precision Medicines Announces Positive Pre-NDA Meeting with FDA for Ulixacaltamide in Essential Tremor
03 Dec 2025 Pengumuman Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
24 Nov 2025 Pengumuman Praxis to present latest preclinical and clinical advancements across leading epilepsy portfolio at the 2025 American Epilepsy Society (AES) Annual Meeting
20 Nov 2025 Pengumuman Praxis Precision Medicines to Participate in Upcoming Fireside Chat
06 Nov 2025 Pengumuman Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05 Nov 2025 Pengumuman Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2025 Financial Results
05 Nov 2025 Pengumuman Praxis Precision Medicines to Participate in Upcoming Investor Conferences
04 Nov 2025 Pengumuman Praxis announces accelerated development path for relutrigine in SCN2A and SCN8A DEE patients following positive FDA feedback
Papar semua

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2026 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda